Divi's Lab. Q4 FY26 Earnings Call — Analysis (NSE: DIVISLAB)
Management guides for double-digit revenue growth in FY27 despite supply-chain disruptions, with stable margins and ongoing heavy capex cycle.
The take
FY26 Total income (FY) ₹11,067 Cr ( +₹1,355 Cr YoY ) . New guidance — FY27 fy27 revenue growth double-digit . New story: Capex cycle building capacity ahead of demand .
Results
Q4FY26 total income ₹2,986 Cr, PAT ₹751 Cr; FY26 total income ₹11,067 Cr (+14% YoY), PAT ₹2,568 Cr (+17% YoY); constant currency growth 6.82%.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total income (Q4) | ₹2,986 Cr | point_in_time · Q4FY26 | |
| PBT (Q4) | ₹963 Cr | +₹99 Cr | yoy · Q4FY26 · Q4FY25: ₹864 Cr |
| PAT (Q4) | ₹751 Cr | point_in_time · Q4FY26 | |
| Total income (FY) | ₹11,067 Cr | +₹1,355 Cr | yoy · FY26 · FY25: ₹9,712 Cr |
| PAT (FY) | ₹2,568 Cr | +₹377 Cr | yoy · FY26 · FY25: ₹2,191 Cr |
| Material consumption | 38.8% | -1.0 pp | yoy · FY26 · FY25: 39.8% |
| Exports share | 89% | point_in_time · FY26 · of total sales | |
| Generics:CS mix | 45:55 | point_in_time · FY26 | |
| Nutraceuticals revenue | ₹946 Cr | +₹165 Cr | yoy · FY26 · FY25: ₹781 Cr |
| Forex gain (FY) | ₹211 Cr | +₹163 Cr | yoy · FY26 · FY25: ₹48 Cr |
| Capex capitalised | ₹1,544 Cr | point_in_time · FY26 | |
| CWIP | ₹2,113 Cr | point_in_time · Mar-26 | |
| Cash | ₹3,414 Cr | point_in_time · Mar-26 | |
| Receivables | ₹2,984 Cr | point_in_time · Mar-26 | |
| Inventories | ₹3,954 Cr | point_in_time · Mar-26 |
Guidance
FY27 revenue growth targeted at double digits; margins expected to remain stable; capex to stay constant unless a major new project emerges.
What management committed to
- Divi's Labs targets double-digit revenue growth in FY27. — double-digit, FY27
- FY27 margins are expected to remain stable. — stable, FY27
- FY27 capex will be constant unless a major custom synthesis project emerges. — constant, FY27
- Commercialisation of at least one of the three dedicated custom synthesis capacities is hoped to occur by 2027. — commercialized, FY27
Key themes
Resilience and capacity-led pipeline build amid external volatility
How the narrative shifted
- Supply-chain resilience amid geopolitical disruption: West Asia conflict causing logistics and raw-material disruptions, but proactive procurement and long-standing partnerships mitigate impact; freight costs rising but no production stoppages.
- Capex cycle building capacity ahead of demand: Large capex program with heavy CWIP and capitalisation in Q4; investments in Unit 3, peptides, and dedicated CS capacities to capture future custom synthesis and generic opportunities, with long-term supply commitments.
- Custom synthesis pipeline progression dependent on customer clocks: Strong project pipeline from early development to validation; three dedicated capacities supplied for approval but commercial start hinges on customer regulatory timelines, which are beyond direct control.
- Generic pricing pressure offset by volume stability: Volumes stable and demand steady, but competitive pricing persists; long-term contracts with variability clauses provide some margin protection.
- Margin outlook stability over expansion: Management declines to project margin expansion, citing raw material and freight cost headwinds, guiding only for stable margins in FY27.
- Peptide ambition as next major growth engine: Building world-scale peptide capabilities with large SPPS reactors, multiple fragment validations, and aspirations to be among global leaders; broad customer engagement across therapeutic areas.
Operational commentary
- Unit 3 ramp-up progressing; select pre-chemistry activities transferred from Unit 1/2 to free up GMP space for customer products.
- Custom synthesis project pipeline active: molecules at various stages from R&D to near-commercialisation; 3 dedicated capacities through validation, awaiting customer regulatory approvals.
- Peptide business deepened: validated several fragments, engaging multiple customers across therapeutic categories; installed large-scale SPPS reactors (3,000-litre).
- Iodine-based contrast media in commercial supply under long-term contracts with major innovators; Gadolinium compounds still in Phase II/III qualification.
- Supply chain disruption from West Asia conflicts; raw materials manageable but freight rates and solvent costs rising; no production stoppages; aggressive procurement securing inventory.
- Generic API volumes stable with steady demand; pricing environment competitive but long-term contracts with variability clauses provide margin protection.
- Technology investments continuing in continuous flow chemistry, biocatalysis, and plant automation.
Analyst Q&A
Q. Is the worst of the raw-material availability issue behind us, and how is methanol sourcing being managed?
Effect limited to 1 month; current environment difficult but no production stoppages; reviewing supply quarterly and securing materials monthly for next 3 months.
Q. Can you pass through raw-material cost inflation in generics?
Most generic APIs backed by long-term contracts with variability clauses reviewed quarterly; spot buys negotiated on case-by-case basis.
Q. Will inventory increase in Q1FY27 due to supply chain issues?
Increase in inventory likely from Q1 but no specific percentage; focus on maintaining production and supply, so some stocking.
Q. Timeline for dedicated CS capacities to start utilisation and required regulatory process?
Validation supplies completed; commercial production depends on customer regulatory approvals; target by 2027 but cannot commit on timeline; regulatory inspection decisions by agencies, not company.
Q. What will be the capex for FY27?
Constant capex expected unless a major new custom synthesis project emerges; capital work-in-progress currently at ₹2,000+ crores.
Q. Details on validated peptide fragments: maximum chain length and number of products?
Cannot disclose due to confidentiality agreements, but healthy pipeline across multiple customers and therapeutic areas.
Research and educational content only. Not investment advice.